Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

10 febbraio 2014 aggiornato da: Boehringer Ingelheim

RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo Controlled, Cohort Dose Escalation Study (RE-DEEM)

The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual antiplatelet treatment in patients with an index event (MI) at high risk for new ischaemic cardiovascular events.

Panoramica dello studio

Stato

Completato

Condizioni

Tipo di studio

Interventistico

Iscrizione (Effettivo)

1878

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Bouge/Namur, Belgio
        • 1160.67.32008 Boehringer Ingelheim Investigational Site
      • Brasschaat, Belgio
        • 1160.67.32011 Boehringer Ingelheim Investigational Site
      • Edegem, Belgio
        • 1160.67.32005 Boehringer Ingelheim Investigational Site
      • Genk, Belgio
        • 1160.67.32002 Boehringer Ingelheim Investigational Site
      • Gilly, Belgio
        • 1160.67.32006 Boehringer Ingelheim Investigational Site
      • Hasselt, Belgio
        • 1160.67.32003 Boehringer Ingelheim Investigational Site
      • Leuven, Belgio
        • 1160.67.32001 Boehringer Ingelheim Investigational Site
      • Tienen, Belgio
        • 1160.67.32004 Boehringer Ingelheim Investigational Site
      • Bourgas, Bulgaria
        • 1160.67.59007 Boehringer Ingelheim Investigational Site
      • Dimitrovgrad, Bulgaria
        • 1160.67.59009 Boehringer Ingelheim Investigational Site
      • Pleven, Bulgaria
        • 1160.67.59003 Boehringer Ingelheim Investigational Site
      • Pleven, Bulgaria
        • 1160.67.59012 Boehringer Ingelheim Investigational Site
      • Rousse, Bulgaria
        • 1160.67.59006 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgaria
        • 1160.67.59001 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgaria
        • 1160.67.59002 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgaria
        • 1160.67.59004 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgaria
        • 1160.67.59005 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgaria
        • 1160.67.59008 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgaria
        • 1160.67.59010 Boehringer Ingelheim Investigational Site
      • Quebec, Canada
        • 1160.67.11014 Boehringer Ingelheim Investigational Site
    • Alberta
      • Calgary, Alberta, Canada
        • 1160.67.11009 Boehringer Ingelheim Investigational Site
    • British Columbia
      • Vancouver, British Columbia, Canada
        • 1160.67.11003 Boehringer Ingelheim Investigational Site
    • Ontario
      • Cambridge, Ontario, Canada
        • 1160.67.11012 Boehringer Ingelheim Investigational Site
      • Hamilton, Ontario, Canada
        • 1160.67.11008 Boehringer Ingelheim Investigational Site
      • London, Ontario, Canada
        • 1160.67.11018 Boehringer Ingelheim Investigational Site
      • Mississauga, Ontario, Canada
        • 1160.67.11017 Boehringer Ingelheim Investigational Site
      • Sudbury, Ontario, Canada
        • 1160.67.11010 Boehringer Ingelheim Investigational Site
      • Sudbury, Ontario, Canada
        • 1160.67.11020 Boehringer Ingelheim Investigational Site
    • Quebec
      • Montreal, Quebec, Canada
        • 1160.67.11004 Boehringer Ingelheim Investigational Site
      • Montreal, Quebec, Canada
        • 1160.67.11016 Boehringer Ingelheim Investigational Site
      • Terrebonne, Quebec, Canada
        • 1160.67.11006 Boehringer Ingelheim Investigational Site
      • Busan, Corea, Repubblica di
        • 1160.67.82010 Boehringer Ingelheim Investigational Site
      • Daegu, Corea, Repubblica di
        • 1160.67.82008 Boehringer Ingelheim Investigational Site
      • Daegu, Corea, Repubblica di
        • 1160.67.82009 Boehringer Ingelheim Investigational Site
      • Daejeon, Corea, Repubblica di
        • 1160.67.82013 Boehringer Ingelheim Investigational Site
      • Daejoen, Corea, Repubblica di
        • 1160.67.82006 Boehringer Ingelheim Investigational Site
      • Incheon, Corea, Repubblica di
        • 1160.67.82007 Boehringer Ingelheim Investigational Site
      • Jeonju, Corea, Repubblica di
        • 1160.67.82012 Boehringer Ingelheim Investigational Site
      • Kwang-Ju, Corea, Repubblica di
        • 1160.67.82005 Boehringer Ingelheim Investigational Site
      • Pusan, Corea, Repubblica di
        • 1160.67.82011 Boehringer Ingelheim Investigational Site
      • Seoul, Corea, Repubblica di
        • 1160.67.82001 Boehringer Ingelheim Investigational Site
      • Seoul, Corea, Repubblica di
        • 1160.67.82002 Boehringer Ingelheim Investigational Site
      • Seoul, Corea, Repubblica di
        • 1160.67.82003 Boehringer Ingelheim Investigational Site
      • Seoul, Corea, Repubblica di
        • 1160.67.82004 Boehringer Ingelheim Investigational Site
      • Aarhus C, Danimarca
        • 1160.67.45001 Boehringer Ingelheim Investigational Site
      • Hvidovre, Danimarca
        • 1160.67.45003 Boehringer Ingelheim Investigational Site
      • Odense, Danimarca
        • 1160.67.45002 Boehringer Ingelheim Investigational Site
      • Roskilde, Danimarca
        • 1160.67.45004 Boehringer Ingelheim Investigational Site
      • Moscow, Federazione Russa
        • 1160.67.70001 Boehringer Ingelheim Investigational Site
      • Moscow, Federazione Russa
        • 1160.67.70002 Boehringer Ingelheim Investigational Site
      • Moscow, Federazione Russa
        • 1160.67.70003 Boehringer Ingelheim Investigational Site
      • Moscow, Federazione Russa
        • 1160.67.70004 Boehringer Ingelheim Investigational Site
      • Moscow, Federazione Russa
        • 1160.67.70005 Boehringer Ingelheim Investigational Site
      • Moscow, Federazione Russa
        • 1160.67.70006 Boehringer Ingelheim Investigational Site
      • Moscow, Federazione Russa
        • 1160.67.70007 Boehringer Ingelheim Investigational Site
      • Saratov, Federazione Russa
        • 1160.67.70010 Boehringer Ingelheim Investigational Site
      • Saratov, Federazione Russa
        • 1160.67.70011 Boehringer Ingelheim Investigational Site
      • St. Petersburg, Federazione Russa
        • 1160.67.70008 Boehringer Ingelheim Investigational Site
      • St. Petersburg, Federazione Russa
        • 1160.67.70009 Boehringer Ingelheim Investigational Site
      • HUS, Finlandia
        • 1160.67.58001 Boehringer Ingelheim Investigational Site
      • Jyväskylä, Finlandia
        • 1160.67.58004 Boehringer Ingelheim Investigational Site
      • Kuopio, Finlandia
        • 1160.67.58003 Boehringer Ingelheim Investigational Site
      • Pori, Finlandia
        • 1160.67.58002 Boehringer Ingelheim Investigational Site
      • Brest Cedex, Francia
        • 1160.67.3305A Boehringer Ingelheim Investigational Site
      • Brest Cedex, Francia
        • 1160.67.3305B Boehringer Ingelheim Investigational Site
      • Dijon Cedex, Francia
        • 1160.67.3303A Boehringer Ingelheim Investigational Site
      • Dijon Cedex, Francia
        • 1160.67.3303B Boehringer Ingelheim Investigational Site
      • Dijon Cedex, Francia
        • 1160.67.3303C Boehringer Ingelheim Investigational Site
      • Dijon Cedex, Francia
        • 1160.67.3303D Boehringer Ingelheim Investigational Site
      • Paris, Francia
        • 1160.67.3301A Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgia
        • 1160.67.95001 Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgia
        • 1160.67.95002 Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgia
        • 1160.67.95003 Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgia
        • 1160.67.95004 Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgia
        • 1160.67.95005 Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgia
        • 1160.67.95006 Boehringer Ingelheim Investigational Site
      • Berlin, Germania
        • 1160.67.49001 Boehringer Ingelheim Investigational Site
      • Berlin, Germania
        • 1160.67.49007 Boehringer Ingelheim Investigational Site
      • Dresden, Germania
        • 1160.67.49017 Boehringer Ingelheim Investigational Site
      • Hannover, Germania
        • 1160.67.49006 Boehringer Ingelheim Investigational Site
      • Homburg/Saar, Germania
        • 1160.67.49019 Boehringer Ingelheim Investigational Site
      • Ludwigshafen am Rhein, Germania
        • 1160.67.49008 Boehringer Ingelheim Investigational Site
      • Neuss, Germania
        • 1160.67.49015 Boehringer Ingelheim Investigational Site
      • Rostock, Germania
        • 1160.67.49004 Boehringer Ingelheim Investigational Site
      • Amedabad, India
        • 1160.67.91004 Boehringer Ingelheim Investigational Site
      • Chennai, India
        • 1160.67.91001 Boehringer Ingelheim Investigational Site
      • Hyderabad, India
        • 1160.67.91005 Boehringer Ingelheim Investigational Site
      • Lucknow, India
        • 1160.67.91007 Boehringer Ingelheim Investigational Site
      • Mumbai, India
        • 1160.67.91002 Boehringer Ingelheim Investigational Site
      • Pune, India
        • 1160.67.91003 Boehringer Ingelheim Investigational Site
      • Pune, India
        • 1160.67.91006 Boehringer Ingelheim Investigational Site
      • Dublin, Irlanda
        • 1160.67.53001 Boehringer Ingelheim Investigational Site
      • Dublin, Irlanda
        • 1160.67.53002 Boehringer Ingelheim Investigational Site
      • Ascoli Piceno, Italia
        • 1160.67.39006 Boehringer Ingelheim Investigational Site
      • Milano, Italia
        • 1160.67.39003 Boehringer Ingelheim Investigational Site
      • Milano, Italia
        • 1160.67.39005 Boehringer Ingelheim Investigational Site
      • Parma, Italia
        • 1160.67.39001 Boehringer Ingelheim Investigational Site
      • S. Maria Capua Vetere (CE), Italia
        • 1160.67.39002 Boehringer Ingelheim Investigational Site
      • Torino, Italia
        • 1160.67.39004 Boehringer Ingelheim Investigational Site
      • Drammen, Norvegia
        • 1160.67.47005 Boehringer Ingelheim Investigational Site
      • Hamar, Norvegia
        • 1160.67.47002 Boehringer Ingelheim Investigational Site
      • Haugesund, Norvegia
        • 1160.67.47003 Boehringer Ingelheim Investigational Site
      • Hønefoss, Norvegia
        • 1160.67.47004 Boehringer Ingelheim Investigational Site
      • Oslo, Norvegia
        • 1160.67.47001 Boehringer Ingelheim Investigational Site
      • Amsterdam, Olanda
        • 1160.67.31001 Boehringer Ingelheim Investigational Site
      • Den Bosch, Olanda
        • 1160.67.31003 Boehringer Ingelheim Investigational Site
      • Den Haag, Olanda
        • 1160.67.31007 Boehringer Ingelheim Investigational Site
      • Ede, Olanda
        • 1160.67.31009 Boehringer Ingelheim Investigational Site
      • Groningen, Olanda
        • 1160.67.31002 Boehringer Ingelheim Investigational Site
      • Helmond, Olanda
        • 1160.67.31006 Boehringer Ingelheim Investigational Site
      • Hoogeveen, Olanda
        • 1160.67.31011 Boehringer Ingelheim Investigational Site
      • Rotterdam, Olanda
        • 1160.67.31005 Boehringer Ingelheim Investigational Site
      • Spijkenisse, Olanda
        • 1160.67.31008 Boehringer Ingelheim Investigational Site
      • Tilburg, Olanda
        • 1160.67.31004 Boehringer Ingelheim Investigational Site
      • Bydgoszcz, Polonia
        • 1160.67.48003 Boehringer Ingelheim Investigational Site
      • Bydgoszcz, Polonia
        • 1160.67.48006 Boehringer Ingelheim Investigational Site
      • Gdynia, Polonia
        • 1160.67.48004 Boehringer Ingelheim Investigational Site
      • Inowroclaw, Polonia
        • 1160.67.48005 Boehringer Ingelheim Investigational Site
      • Sopot, Polonia
        • 1160.67.48002 Boehringer Ingelheim Investigational Site
      • Warsaw, Polonia
        • 1160.67.48001 Boehringer Ingelheim Investigational Site
      • Brighton, Regno Unito
        • 1160.67.44003 Boehringer Ingelheim Investigational Site
      • Exeter, Regno Unito
        • 1160.67.44002 Boehringer Ingelheim Investigational Site
      • Middlesbrough, Regno Unito
        • 1160.67.44001 Boehringer Ingelheim Investigational Site
      • Hradec Kralove, Repubblica Ceca
        • 1160.67.42007 Boehringer Ingelheim Investigational Site
      • Litomerice, Repubblica Ceca
        • 1160.67.42005 Boehringer Ingelheim Investigational Site
      • Ostrava, Repubblica Ceca
        • 1160.67.42008 Boehringer Ingelheim Investigational Site
      • Prague, Repubblica Ceca
        • 1160.67.42001 Boehringer Ingelheim Investigational Site
      • Teplice, Repubblica Ceca
        • 1160.67.42003 Boehringer Ingelheim Investigational Site
      • Zlin, Repubblica Ceca
        • 1160.67.42002 Boehringer Ingelheim Investigational Site
      • Baia Mare, Romania
        • 1160.67.40006 Boehringer Ingelheim Investigational Site
      • Braila, Romania
        • 1160.67.40005 Boehringer Ingelheim Investigational Site
      • Bucharest, Romania
        • 1160.67.40001 Boehringer Ingelheim Investigational Site
      • Bucharest, Romania
        • 1160.67.40003 Boehringer Ingelheim Investigational Site
      • Bucharest, Romania
        • 1160.67.40004 Boehringer Ingelheim Investigational Site
      • Oradea, Romania
        • 1160.67.40002 Boehringer Ingelheim Investigational Site
      • Tg. Mures, Romania
        • 1160.67.40007 Boehringer Ingelheim Investigational Site
      • Barcelona, Spagna
        • 1160.67.34001 Boehringer Ingelheim Investigational Site
      • Barcelona, Spagna
        • 1160.67.34002 Boehringer Ingelheim Investigational Site
      • Madrid, Spagna
        • 1160.67.34005 Boehringer Ingelheim Investigational Site
      • Madrid, Spagna
        • 1160.67.34006 Boehringer Ingelheim Investigational Site
      • Sabadell (Barcelona), Spagna
        • 1160.67.34003 Boehringer Ingelheim Investigational Site
      • Tarragona, Spagna
        • 1160.67.34004 Boehringer Ingelheim Investigational Site
    • Florida
      • Clearwater, Florida, Stati Uniti
        • 1160.67.10002 Boehringer Ingelheim Investigational Site
      • Göteborg, Svezia
        • 1160.67.46004 Boehringer Ingelheim Investigational Site
      • Göteborg, Svezia
        • 1160.67.46006 Boehringer Ingelheim Investigational Site
      • Malmö, Svezia
        • 1160.67.46007 Boehringer Ingelheim Investigational Site
      • Motala, Svezia
        • 1160.67.46005 Boehringer Ingelheim Investigational Site
      • Stockholm, Svezia
        • 1160.67.46002 Boehringer Ingelheim Investigational Site
      • Uppsala, Svezia
        • 1160.67.46001 Boehringer Ingelheim Investigational Site
      • Vaesteraas, Svezia
        • 1160.67.46003 Boehringer Ingelheim Investigational Site
      • Ivano-Frankovsk, Ucraina
        • 1160.67.38002 Boehringer Ingelheim Investigational Site
      • Kharkov, Ucraina
        • 1160.67.38004 Boehringer Ingelheim Investigational Site
      • Kharkov, Ucraina
        • 1160.67.38007 Boehringer Ingelheim Investigational Site
      • Kiev, Ucraina
        • 1160.67.38001 Boehringer Ingelheim Investigational Site
      • Kiev, Ucraina
        • 1160.67.38003 Boehringer Ingelheim Investigational Site
      • Kiev, Ucraina
        • 1160.67.38005 Boehringer Ingelheim Investigational Site
      • Nikolayev, Ucraina
        • 1160.67.38008 Boehringer Ingelheim Investigational Site
      • Odessa, Ucraina
        • 1160.67.38006 Boehringer Ingelheim Investigational Site
      • Budapest, Ungheria
        • 1160.67.36001 Boehringer Ingelheim Investigational Site
      • Budapest, Ungheria
        • 1160.67.36003 Boehringer Ingelheim Investigational Site
      • Budapest, Ungheria
        • 1160.67.36004 Boehringer Ingelheim Investigational Site
      • Debrecen, Ungheria
        • 1160.67.36002 Boehringer Ingelheim Investigational Site
      • Kecskemet, Ungheria
        • 1160.67.36007 Boehringer Ingelheim Investigational Site
      • Komarom, Ungheria
        • 1160.67.36006 Boehringer Ingelheim Investigational Site
      • Miskolc, Ungheria
        • 1160.67.36008 Boehringer Ingelheim Investigational Site
      • Mosonmagyarovar, Ungheria
        • 1160.67.36009 Boehringer Ingelheim Investigational Site
      • Zalaegerszeg, Ungheria
        • 1160.67.36005 Boehringer Ingelheim Investigational Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion criteria Patients with acute coronary syndromes with at least one additional risk factor for cardiovascular complications.

Exclusion criteria

  1. Long term treatment with any other oral anticoagulant
  2. Severe/disabling stroke within last 6 months
  3. Conditions associated with increased bleeding risk
  4. Anaemia or thrombocytopenia
  5. Severe renal impairment
  6. Liver disease
  7. Positive pregnancy test

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: placebo
placebo abbinato
placebo abbinato
Sperimentale: Dabigatran etexilate 50mg
twice daily dosing,
capsules, twice daily, 26 weeks treatment
Sperimentale: Dabigatran etexilate 75mg
twice daily dosing, patients with moderate renal impairment allocated 50mg bid
capsules, twice daily, 26 weeks treatment
Sperimentale: Dabigatran etexilate 110mg
twice daily dosing, patients with moderate renal impairment allocated 75mg bid
capsules, twice daily, 26 weeks treatment
Sperimentale: dabigatran etexilate 150mg
twice daily dosing, patients with moderate renal impairment allocated 110mg bid
capsules, twice daily, 26 weeks treatment

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Participants Displaying the Composite of Major and Clinically Relevant Minor Bleeding Events During Total Observation Time
Lasso di tempo: 6 month treatment period + 2 week post treatment follow up

International Society Thrombosis and Haemostasis (ISTH) definition of a major bleed, and clinically relevant minor bleed.

A bleeding event was considered as major if it was fatal, was a symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or caused a fall in haemoglobin level of ≥2 g/dL (≥1.24 mmol/L), or led to transfusion of ≥2 units of whole blood or red cells.

All non major bleeding events were classified as minor bleeds; minor bleeds were subdivided in clinically relevant minor bleeds and not clinically relevant minor bleeds. A CRBE was defined as an acute or subacute clinically overt bleed that did not meet the criteria of a major bleed but either lead to hospital admission and/or a physician guided medical or surgical treatment and/or a change in antithrombotic therapy (including interruption or discontinuation of study drug).

6 month treatment period + 2 week post treatment follow up

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Composite of Cardiovascular Death (CVD) With Non Fatal Myocardial Infarction (MI) and Non Haemorrhagic Stroke and All Cause Death (ACD), Non Fatal MI, Severe Recurrent Ischaemia (SRI) and Non Haemorrhagic Stroke During Six Months Treatment
Lasso di tempo: 6 month treatment period + 2 week post treatment follow up
Number of Participants with Composite of Cardiovascular death (CVD) with non fatal myocardial infarction (MI) and non haemorrhagic stroke and All cause death (ACD), non fatal MI, severe recurrent ischaemia (SRI) and non haemorrhagic stroke during six months treatment
6 month treatment period + 2 week post treatment follow up
Individual Occurrence of Death (Cardiovascular and All-cause), Non-fatal MI, Severe Recurrent Ischaemia and Non-haemorrhagic Stroke During Six Months of Treatment
Lasso di tempo: 6 month treatment period + 2 week post treatment follow up
Number of Participants with individual occurrence of death (cardiovascular and all-cause), non-fatal MI, severe recurrent ischaemia and non-haemorrhagic stroke during six months of treatment.
6 month treatment period + 2 week post treatment follow up
Number of Participants With Any Reduction of D-dimer Concentration
Lasso di tempo: at 1 week and 4 weeks
at 1 week and 4 weeks
Change From Baseline in log10 D-dimer After 1 and 4 Weeks
Lasso di tempo: Baseline and at 1 week and 4 weeks
Change from baseline in log10 D-dimer concentration after 1 and 4 weeks of dabigatran etexilate treatment compared to placebo. The standard deviation is the geometric standard deviation.
Baseline and at 1 week and 4 weeks
Number of Participants With Bleeding Events During Total Observation Time
Lasso di tempo: 6 month treatment period + 2 week post treatment follow up

International Society Thrombosis and Haemostasis (ISTH) definition of a major bleed, and clinically relevant minor bleed.

A bleeding event was considered as major if it was fatal, was a symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or caused a fall in haemoglobin level of ≥2 g/dL (≥1.24 mmol/L), or led to transfusion of ≥2 units of whole blood or red cells.

All non major bleeding events were classified as minor bleeds; minor bleeds were subdivided in clinically relevant minor bleeds (CRBE) and not clinically relevant minor bleeds. A CRBE was defined as an acute or subacute clinically overt bleed that did not meet the criteria of a major bleed but either lead to hospital admission and/or a physician guided medical or surgical treatment and/or a change in antithrombotic therapy (including interruption or discontinuation of study drug).

6 month treatment period + 2 week post treatment follow up
Laboratory Analyses
Lasso di tempo: 6 month treatment period + 2 week post treatment follow up
Number of patients with possible clinically significant abnormalities. Clinically significant abnormalities refers to the increase or decrease from baseline.
6 month treatment period + 2 week post treatment follow up

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Collegamenti utili

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 marzo 2008

Completamento primario (Effettivo)

1 ottobre 2009

Date di iscrizione allo studio

Primo inviato

13 febbraio 2008

Primo inviato che soddisfa i criteri di controllo qualità

21 febbraio 2008

Primo Inserito (Stima)

22 febbraio 2008

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

12 marzo 2014

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 febbraio 2014

Ultimo verificato

1 febbraio 2014

Maggiori informazioni

Termini relativi a questo studio

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi